Navigation Links
Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
Date:7/22/2010

KING OF PRUSSIA, Pa., July 22 /PRNewswire/ -- Recovering unnecessarily lost patient information is now a viable reality.  Lost to follow up (L2FU) rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.

Consequently, regulatory agencies such as the FDA, are requesting that clinical trial sponsors perform comprehensive follow up measures as part of a clinical trial's due diligence efforts or during the conduct of long term safety surveillance studies to monitor patient outcomes.

L2FU, a company specializing in helping clinical trial sites and biopharma companies to locate, contact and collect data from patients deemed 'Lost to Follow-Up', is building a portfolio of successes and an industry reputation for its quality work. The L2FU team proudly reports its latest successful recovery of 100% of a recent study's lost clinical trial patients. This was achieved in only one month to meet a truncated timeline.  The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.

The L2FU team worked diligently to recover the lost patients, who were located in other states while acquiring new addresses. "Finding these lost patients several years after their clinical trial participation goes a long way to ensuring that our client's study meets its primary endpoints, and that all of their data is accepted by the Food and Drug Administration (FDA)," noted Bernard Hall, L2FU's manager and main point of contact.

L2FU works closely with clinical research sites and data managers at clinical research organizations (CROs) and biopharmaceutical companies to transmit collected patient data in a secure manner; adhering to HIPAA regulations for privacy and data security. The L2FU team is experienced in proactively recovering lost study subjects and sensitively communicating with patients and their families. Team members are trained on the procedures required for the licensed access to many databases containing millions of vital records.

Employing L2FU to manage lost patients allows already overworked study coordinators to focus their time on active patients in the study, and the L2FU team provides clinical trial sponsors the reassurance that missing patients and required outcome data will be accounted for.

L2FU is part of MediciGlobal, a global leader in the recruitment and retention of patients for clinical trials. With more than 20 years of clinical trials experience in patient recruitment-retention, MediciGlobal is a company dedicated to the recruitment-retention and reconnection of patients for clinical trials.  For more information on L2FU visit http://www.L2FU.com or call Bernard Hall at 484-674-6816.


'/>"/>
SOURCE MediciGlobal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
2. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
3. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
4. Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership
5. Innovative Partnership Helps Improve Medical Research by Optimizing Clinical Trials
6. Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
7. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
8. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
9. ISTA Pharmaceuticals Initiates Clinical Development of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
11. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016   ... endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of the ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced new ... litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG ...
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical ... and treat patients on a global scale. Medical professionals from ... Asia and the US have already signed up for ... in a totally secure environment. Education  "Imagine ... together with a surgeon at Harvard to treat a bomb victim ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... The Woodlands at John Knox Village , Florida’s ... care for living and healing, celebrated its grand opening, today. The Woodlands at John ... provided by Empowered Staff. , “This is an incredibly fulfilling time for John Knox ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... Wash. (PRWEB) , ... May 26, 2016 , ... ... trusted provider of comprehensive treatment for eating disorders, is opening a brand new ... will provide individuals ages 8-17 and their families with even more specialized eating ...
(Date:5/26/2016)... Miami, FL (PRWEB) , ... May 26, 2016 , ... ... day of events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis ... Anti-Aging and Regenerative Medicine, and a member of the Institute for Functional Medicine. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
Breaking Medicine News(10 mins):